SCHEDULE 13G/A: Sanofi Discloses 9.05% Stake in Innate Pharma SA via Amended SEC Filing

Sanofi has filed an amended Schedule 13G, revealing its beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares as of April 23, 2025.

Summary

• Sanofi, a French-based entity, reported beneficial ownership of 8,345,387 ordinary shares of Innate Pharma SA.
• This stake represents 9.05% of Innate Pharma SA's total outstanding ordinary shares, calculated based on 92,157,148 shares outstanding as of April 25, 2025, as reported by the Issuer.
• Sanofi holds sole voting power and sole dispositive power over all 8,345,387 shares.
• The shares are held of record by Sanofi-Aventis Participations SAS, which is an indirect, wholly-owned subsidiary of Sanofi.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously filed statement of beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It is an amendment, but the specific change from the previous filing is not detailed to assess an increase or decrease in stake.

Future Outlook

NA

Industry Context

This filing indicates a significant equity stake by a major global pharmaceutical company (Sanofi) in a biotechnology firm (Innate Pharma SA). Such investments are common in the pharmaceutical and biotechnology sectors, often signaling strategic partnerships, collaborations, or potential future corporate actions, although this document solely discloses the ownership position.

Related Party Transactions

• The 8,345,387 ordinary shares of Innate Pharma SA are held of record by Sanofi-Aventis Participations SAS, which is an indirect, wholly-owned subsidiary of Sanofi. This represents an internal corporate structure for holding the investment.

Stakeholder Impact

• Shareholders of Innate Pharma SA: Sanofi's significant 9.05% stake could influence corporate governance, strategic decisions, and potentially future corporate actions (e.g., partnerships, acquisitions), which could impact shareholder value.
• Shareholders of Sanofi: The investment in Innate Pharma SA represents a strategic asset for Sanofi, potentially contributing to its pharmaceutical pipeline or market position.

Key Dates

Keywords

Sanofi, Innate Pharma SA, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Pharmaceuticals, Biotechnology, Equity Stake, Institutional Ownership